查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949621

經腸營養市場－全球產業規模、佔有率、趨勢、機會及預測（依產品、流型、階段、適應症、最終用途、地區及競爭格局分類，2021-2031年）

Enteral Feeding Formulas Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Flow Type, By Stage, By Indication, By End-Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球經腸營養市場預計將從 2025 年的 68.5 億美元成長到 2031 年的 99.7 億美元，複合年成長率為 6.46%。

這些營養配方是專為難以口服營養的患者設計的特殊液體營養製劑，透過導管直接輸送到消化道。市場成長的促進因素包括全球慢性病負擔日益加重以及人口快速老化，這些因素都需要持續的營養支持。此外，居家醫療保健的趨勢也加速了市場需求，因為它提供了比長期住院治療更經濟有效的替代方案。國際醫療營養產業協會強調了臨床營養干預的迫切性，指出到2025年，歐洲將有3,300萬人營養不良或面臨營養不良的風險。

市場概覽
預測期 2027-2031
市場規模：2025年 68.5億美元
市場規模：2031年 99.7億美元
複合年成長率：2026-2031年 6.46%
成長最快的細分市場 標準型
最大的市場 北美洲

然而，各地區複雜的健保報銷環境嚴重阻礙了市場擴張。保險覆蓋範圍的不統一，尤其是在居家照護中使用的配方奶粉，造成了經濟障礙，限制了許多患者的獲取途徑和負擔能力。這些經濟限制可能會阻礙患者及時開始必要的營養治療，尤其是在價格敏感型經濟體中，自付費用是主要考慮因素，從而限制了整體市場成長。

市場促進因素

全球慢性疾病（尤其是胃腸道疾病和癌症）盛行率的不斷上升，是推動經腸營養市場成長的主要因素。長期患病的患者往往營養不良嚴重，吞嚥功能受損，需要臨床營養介入以維持生理穩定。惡性腫瘤發生率的不斷上升，以及化療等積極治療手段的增多，進一步刺激了這項需求。這些治療通常會阻礙患者經口進食，需要管飼才能復原。根據美國癌症協會於2025年1月發布的《2025年癌症事實與數據》報告，預計僅在美國就將新增2,041,910例癌症病例，凸顯了需要營養支持的患者群體不斷擴大。

隨著疾病負擔的日益加重，針對特定疾病的個人化配方應運而生，進一步推動了市場發展，滿足個體代謝需求。製造商正在研發針對糖尿病、腎衰竭和吸收不良等疾病的營養配方，與標準聚合物配方相比，這些配方能夠改善臨床療效並提高患者耐受性。這種對個人化營養的關注正在推動主要企業營收成長。例如，達能公司在2025年2月發布的「2024會計年度全年業績報告」中，其特種營養品部門的銷售額成長了4.6%。同樣，費森尤斯公司在2025年公佈的營養品業務部門2024會計年度銷售額成長了4%，總額達到24億歐元，反映出整個行業的強勁成長勢頭。

市場挑戰

全球經腸營養市場面臨的主要經濟障礙之一是複雜的報銷體系。嚴格的資格標準和不一致的區域保險政策給看護者和患者帶來了沉重的經濟負擔，尤其是在不斷發展的居家醫療領域。當第三方支付方對這些重要的營養製劑的報銷不足或拒付時，由此產生的高額自付費用往往會阻礙患者開始或繼續必要的長期治療。這種經濟摩擦直接限制了產品的使用，並抑制了收入潛力，尤其是在價格敏感型經濟體中。

此外，報銷相關的行政負擔也使得醫療機構難以維持充足的特殊營養配方庫存。 2025年，美國腸內腸外營養學會指出，由於某些監管調整措施的到期，許多居家醫療設備供應商的報銷率下降了30%以上，嚴重影響了其提供經腸營養資源的運作能力。這種財務上的不穩定性迫使醫療機構縮減服務範圍，從而限制了患者的就醫途徑，並直接阻礙了市場的整體成長。

市場趨勢

製造商正擴大將免疫調節營養素（例如核苷酸、精氨酸和Omega-3脂肪酸）添加到旨在支持術前和重症監護患者康復的配方中。這種對代謝支持和免疫營養的關注旨在應對重症監護患者所經歷的急性生理應激，這與通常推動需求的慢性病管理領域截然不同。這種對高度急性照護的策略性關注正在推動市場領導取得強勁的財務表現。例如，費森尤斯卡比公司於2025年3月發布的2024年度報告顯示，其臨床營養業務部門實現了13%的有機銷售成長，這主要得益於其在重症監護領域地位的提升。

與臨床配方技術的進步相呼應的是，配方正發生顯著變化，不再僅依賴合成營養素，而是更多地採用肉類、蔬菜和水果等全食物成分。這種朝向「真食物」和攪拌機加工解決方案的轉變，源自於消費者對「潔淨標示」產品的需求。這些產品模擬天然飲食，據報導有助於改善長期使用者的心理健康和腸胃耐受性。這一趨勢的商業性影響顯而易見。雀巢健康科學在其2024年11月的「資本市場日」活動中透露，其醫療營養業務在全球範圍內實現了兩位數的成長，這在很大程度上得益於其植物來源和「真食物」產品線的強勁市場表現。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球經腸營養市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品分類（標準配方、疾病特異性配方）
    • 依流量類型（間歇性營養供應流量、連續性營養供應流量）
    • 依階段（成人、兒童）
    • 根據適應症（阿茲海默症、營養缺乏、癌症治療、糖尿病、慢性腎臟病、罕見疾病、吞嚥障礙、疼痛管理、吸收不良/胃腸道疾病/腹瀉、其他）
    • 按用途（醫院、居家醫療）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美經腸營養市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲經腸營養市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區經腸營養市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲經腸營養市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美經腸營養市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球經腸營養市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Inc
  • Danone SA
  • Fresenius Kabi AG
  • Nestle SA
  • VICTUS Inc.
  • Primus Pharmaceuticals, Inc.
  • Meiji Holdings. Co Ltd.
  • Mead Johnson & Company, LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17206

The Global Enteral Feeding Formulas Market is projected to expand from USD 6.85 Billion in 2025 to USD 9.97 Billion by 2031, registering a CAGR of 6.46%. These formulas consist of specialized liquid nutritional compositions administered directly into the gastrointestinal tract via a tube, designed for patients who cannot consume food orally. The market's growth is driven by the increasing global burden of chronic diseases and a rapidly aging population that necessitates consistent nutritional support. Furthermore, the trend toward home-based healthcare is accelerating demand by offering a cost-effective alternative to extended hospital stays. Underscoring the urgency for clinical nutrition interventions, the Medical Nutrition International Industry highlighted in 2025 that 33 million individuals in Europe were either malnourished or at risk of malnutrition.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.85 Billion
Market Size 2031USD 9.97 Billion
CAGR 2026-20316.46%
Fastest Growing SegmentStandard Formula
Largest MarketNorth America

However, market expansion is significantly hindered by a complex reimbursement landscape across various regions. Inconsistent insurance coverage, particularly for formulas used in home care settings, creates financial obstacles that limit accessibility and affordability for many patients. These economic constraints can impede the timely initiation of essential nutritional therapy and restrict overall market growth, especially in price-sensitive economies where out-of-pocket costs are a major concern.

Market Driver

The rising global prevalence of chronic diseases, specifically gastrointestinal disorders and cancer, acts as a major catalyst for the growth of the enteral feeding formulas market. Patients dealing with these long-term conditions often face severe malnutrition or compromised swallowing abilities, requiring clinical nutritional interventions to maintain physiological stability. This demand is further intensified by the increasing incidence of malignancies necessitating aggressive treatments like chemotherapy, which often impair oral intake and mandate tube feeding for recovery. The American Cancer Society's 'Cancer Facts & Figures 2025' report, released in January 2025, projected 2,041,910 new cancer diagnoses in the United States alone, highlighting the expanding patient pool in need of supportive nutritional care.

Alongside rising disease burdens, the market is bolstered by advancements in personalized and disease-specific formulas tailored to meet unique metabolic needs. Manufacturers are developing specialized compositions for conditions like diabetes, renal failure, and malabsorption, which offer improved clinical outcomes and patient tolerance compared to standard polymeric feeds. This focus on tailored nutrition has driven revenue growth for key players; for example, Danone reported in its 'Full Year 2024 Results' in February 2025 that sales in its Specialized Nutrition division rose by 4.6%. Similarly, Fresenius reported in 2025 that its Nutrition business segment achieved a revenue increase of 4%, totaling €2.4 billion for the fiscal year 2024, reflecting strong sector-wide momentum.

Market Challenge

A primary economic barrier impeding the Global Enteral Feeding Formulas Market is the complex reimbursement landscape. Restrictive coverage criteria and inconsistent insurance policies across different regions create substantial financial liabilities for caregivers and patients, especially within the expanding home care sector. When third-party payers provide inadequate funding or deny claims for these vital nutritional compositions, the resulting high out-of-pocket costs frequently discourage patients from starting or continuing necessary long-term therapy. This economic friction directly limits product utilization volume and stifles revenue potential, particularly in economies where price sensitivity is high.

Additionally, the administrative burden involved in securing reimbursement deters suppliers from keeping robust inventories of specialized formulas. In 2025, the American Society for Parenteral and Enteral Nutrition noted that the expiration of specific regulatory adjustments led to reimbursement rate cuts of over 30% for many home medical equipment suppliers, severely straining their operational capacity to provide enteral nutrition resources. Such financial instability compels providers to limit their service offerings, thereby restricting patient access and directly hampering the market's overall growth trajectory.

Market Trends

Manufacturers are increasingly integrating immune-modulating nutrients, such as nucleotides, arginine, and omega-3 fatty acids, into formulations aimed at supporting recovery in pre-operative and critical care environments. This emphasis on metabolic support and immunonutrition addresses the acute physiological stress experienced by intensive care patients, a segment distinct from the chronic disease management that typically drives volume. This strategic focus on high-acuity therapies has resulted in strong financial performance for market leaders; for example, Fresenius Kabi's 'Annual Report 2024', published in March 2025, reported that its Clinical Nutrition business segment achieved a 13% organic revenue increase, driven by its strengthening position in critical care therapies.

Parallel to the advancement of clinical formulations, there is a significant shift toward formulas containing whole-food ingredients like meats, vegetables, and fruits, rather than relying solely on synthetic nutrients. This movement toward "real food" and blenderized solutions is fueled by the demand for "clean label" products that mimic a natural diet, which reportedly enhances psychological well-being and gastrointestinal tolerance for long-term users. The commercial impact of this trend is evident; Nestle Health Science revealed in its November 2024 'Capital Markets Day' presentation that its Medical Nutrition business achieved double-digit growth globally, significantly propelled by the robust adoption of its plant-based and "real food" product lines.

Key Market Players

  • Abbott Laboratories Inc
  • Danone S.A
  • Fresenius Kabi AG
  • Nestle S.A.
  • VICTUS Inc.
  • Primus Pharmaceuticals, Inc.
  • Meiji Holdings. Co Ltd.
  • Mead Johnson & Company, LLC

Report Scope

In this report, the Global Enteral Feeding Formulas Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Enteral Feeding Formulas Market, By Product

  • Standard Formula
  • Disease-specific Formulas

Enteral Feeding Formulas Market, By Flow Type

  • Intermittent Feeding Flow
  • Continuous Feeding Flow

Enteral Feeding Formulas Market, By Stage

  • Adults
  • Pediatrics

Enteral Feeding Formulas Market, By Indication

  • Alzheimer's
  • Nutrition Deficiency
  • Cancer Care
  • Diabetes
  • Chronic Kidney Diseases
  • Orphan Diseases
  • Dysphagia
  • Pain Management
  • Malabsorption/GI Disorder/Diarrhea
  • Others

Enteral Feeding Formulas Market, By End-Use

  • Hospitals
  • Homecare

Enteral Feeding Formulas Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Enteral Feeding Formulas Market.

Available Customizations:

Global Enteral Feeding Formulas Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Enteral Feeding Formulas Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Standard Formula, Disease-specific Formulas)
    • 5.2.2. By Flow Type (Intermittent Feeding Flow, Continuous Feeding Flow)
    • 5.2.3. By Stage (Adults, Pediatrics)
    • 5.2.4. By Indication (Alzheimer's, Nutrition Deficiency, Cancer Care, Diabetes, Chronic Kidney Diseases, Orphan Diseases, Dysphagia, Pain Management, Malabsorption/GI Disorder/Diarrhea, Others)
    • 5.2.5. By End-Use (Hospitals, Homecare)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Enteral Feeding Formulas Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Flow Type
    • 6.2.3. By Stage
    • 6.2.4. By Indication
    • 6.2.5. By End-Use
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Enteral Feeding Formulas Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Flow Type
        • 6.3.1.2.3. By Stage
        • 6.3.1.2.4. By Indication
        • 6.3.1.2.5. By End-Use
    • 6.3.2. Canada Enteral Feeding Formulas Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Flow Type
        • 6.3.2.2.3. By Stage
        • 6.3.2.2.4. By Indication
        • 6.3.2.2.5. By End-Use
    • 6.3.3. Mexico Enteral Feeding Formulas Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Flow Type
        • 6.3.3.2.3. By Stage
        • 6.3.3.2.4. By Indication
        • 6.3.3.2.5. By End-Use

7. Europe Enteral Feeding Formulas Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Flow Type
    • 7.2.3. By Stage
    • 7.2.4. By Indication
    • 7.2.5. By End-Use
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Enteral Feeding Formulas Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Flow Type
        • 7.3.1.2.3. By Stage
        • 7.3.1.2.4. By Indication
        • 7.3.1.2.5. By End-Use
    • 7.3.2. France Enteral Feeding Formulas Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Flow Type
        • 7.3.2.2.3. By Stage
        • 7.3.2.2.4. By Indication
        • 7.3.2.2.5. By End-Use
    • 7.3.3. United Kingdom Enteral Feeding Formulas Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Flow Type
        • 7.3.3.2.3. By Stage
        • 7.3.3.2.4. By Indication
        • 7.3.3.2.5. By End-Use
    • 7.3.4. Italy Enteral Feeding Formulas Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Flow Type
        • 7.3.4.2.3. By Stage
        • 7.3.4.2.4. By Indication
        • 7.3.4.2.5. By End-Use
    • 7.3.5. Spain Enteral Feeding Formulas Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Flow Type
        • 7.3.5.2.3. By Stage
        • 7.3.5.2.4. By Indication
        • 7.3.5.2.5. By End-Use

8. Asia Pacific Enteral Feeding Formulas Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Flow Type
    • 8.2.3. By Stage
    • 8.2.4. By Indication
    • 8.2.5. By End-Use
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Enteral Feeding Formulas Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Flow Type
        • 8.3.1.2.3. By Stage
        • 8.3.1.2.4. By Indication
        • 8.3.1.2.5. By End-Use
    • 8.3.2. India Enteral Feeding Formulas Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Flow Type
        • 8.3.2.2.3. By Stage
        • 8.3.2.2.4. By Indication
        • 8.3.2.2.5. By End-Use
    • 8.3.3. Japan Enteral Feeding Formulas Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Flow Type
        • 8.3.3.2.3. By Stage
        • 8.3.3.2.4. By Indication
        • 8.3.3.2.5. By End-Use
    • 8.3.4. South Korea Enteral Feeding Formulas Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Flow Type
        • 8.3.4.2.3. By Stage
        • 8.3.4.2.4. By Indication
        • 8.3.4.2.5. By End-Use
    • 8.3.5. Australia Enteral Feeding Formulas Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Flow Type
        • 8.3.5.2.3. By Stage
        • 8.3.5.2.4. By Indication
        • 8.3.5.2.5. By End-Use

9. Middle East & Africa Enteral Feeding Formulas Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Flow Type
    • 9.2.3. By Stage
    • 9.2.4. By Indication
    • 9.2.5. By End-Use
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Enteral Feeding Formulas Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Flow Type
        • 9.3.1.2.3. By Stage
        • 9.3.1.2.4. By Indication
        • 9.3.1.2.5. By End-Use
    • 9.3.2. UAE Enteral Feeding Formulas Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Flow Type
        • 9.3.2.2.3. By Stage
        • 9.3.2.2.4. By Indication
        • 9.3.2.2.5. By End-Use
    • 9.3.3. South Africa Enteral Feeding Formulas Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Flow Type
        • 9.3.3.2.3. By Stage
        • 9.3.3.2.4. By Indication
        • 9.3.3.2.5. By End-Use

10. South America Enteral Feeding Formulas Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Flow Type
    • 10.2.3. By Stage
    • 10.2.4. By Indication
    • 10.2.5. By End-Use
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Enteral Feeding Formulas Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Flow Type
        • 10.3.1.2.3. By Stage
        • 10.3.1.2.4. By Indication
        • 10.3.1.2.5. By End-Use
    • 10.3.2. Colombia Enteral Feeding Formulas Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Flow Type
        • 10.3.2.2.3. By Stage
        • 10.3.2.2.4. By Indication
        • 10.3.2.2.5. By End-Use
    • 10.3.3. Argentina Enteral Feeding Formulas Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Flow Type
        • 10.3.3.2.3. By Stage
        • 10.3.3.2.4. By Indication
        • 10.3.3.2.5. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Enteral Feeding Formulas Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Danone S.A
  • 15.3. Fresenius Kabi AG
  • 15.4. Nestle S.A.
  • 15.5. VICTUS Inc.
  • 15.6. Primus Pharmaceuticals, Inc.
  • 15.7. Meiji Holdings. Co Ltd.
  • 15.8. Mead Johnson & Company, LLC

16. Strategic Recommendations

17. About Us & Disclaimer